# Diagnostics — company-by-company sector analysis

> Diagnostics: Dr Lal Pathlabs Ltd owns the largest revenue base; One Global Service Provider Ltd has the fastest current growth.

Sector Alpha — machine-written from the numbers. Data as of 2026-08-05. Not investment advice.

## Bottom line

Diagnostics has outperformed NIFTY 500 by 10.9% over 52 weeks and 15.5% over 13 weeks. 6 of 9 covered companies beat NIFTY on Mansfield relative strength, while 5 of 9 beat the sector itself. Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 9 of 9 comparable companies through Jun 2026.

## Sector relative strength

Diagnostics has outperformed NIFTY 500 by 10.9% over the last 52 weeks. Over 13 weeks the gap is a lead of 15.5%. 6 of 9 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Thyrocare Technologies Ltd is the strongest against the sector itself at +16.8%. Readings are as of 2026-07-19.

13-week sector return versus NIFTY 500: 16%
52-week sector return versus NIFTY 500: 11%
Stocks leading NIFTY: 6/9
Stocks leading sector: 5/9

Central tension: The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Companies: 9
Combined market value: ₹75.0K Cr

## 4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

1. Thyrocare Technologies Ltd (THYROCARE): 77/100 — Favorable setup; evidence 100%
   - Growth & earnings 27.9/35 | Capital efficiency 18.1/25 | Valuation 12.0/20 | Relative strength 19.4/20
   - Price stage: LEADER — Ahead of the benchmark 13 weeks or more running, and ahead over the past year.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 12 of the last 12 weeks
   - Exact sum: 27.9 + 18.1 + 12 + 19.4 = 77.4
   - Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2. Dr Lal Pathlabs Ltd (LALPATHLAB): 63/100 — Mixed-positive evidence; evidence 100%
   - Growth & earnings 14.6/35 | Capital efficiency 16.8/25 | Valuation 13.0/20 | Relative strength 18.9/20
   - Price stage: LEADER — Ahead of the benchmark 13 weeks or more running, and ahead over the past year.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 12 of the last 12 weeks
   - Exact sum: 14.6 + 16.8 + 13 + 18.9 = 63.3
   - Decision use: Price leads the evidence: RS versus the benchmark is 22.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
3. Metropolis Healthcare Ltd (METROPOLIS): 60/100 — Mixed-positive evidence; evidence 96%
   - Growth & earnings 27.2/35 | Capital efficiency 11.7/25 | Valuation 6.3/20 | Relative strength 14.9/20
   - Price stage: LEADER — Ahead of the benchmark 13 weeks or more running, and ahead over the past year.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 12 of the last 12 weeks
   - Exact sum: 27.2 + 11.7 + 6.3 + 14.9 = 60.1
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4. One Global Service Provider Ltd (514330): 60/100 — Mixed-positive evidence; evidence 78%
   - Growth & earnings 24.9/35 | Capital efficiency 16.5/25 | Valuation 10.1/20 | Relative strength 8.3/20
   - Price stage: TURNING — Ahead of the benchmark for one to four weeks, after a stretch of being behind.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 2 of the last 12 weeks
   - Exact sum: 24.9 + 16.5 + 10.1 + 8.3 = 59.8
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5. Vijaya Diagnostic Centre Ltd (VIJAYA): 59/100 — Mixed-positive evidence; evidence 96%
   - Growth & earnings 20.1/35 | Capital efficiency 18.5/25 | Valuation 6.4/20 | Relative strength 13.8/20
   - Price stage: LEADER — Ahead of the benchmark 13 weeks or more running, and ahead over the past year.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 12 of the last 12 weeks
   - Exact sum: 20.1 + 18.5 + 6.4 + 13.8 = 58.8
   - Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
6. 3B Blackbio DX Ltd (3BBLACKBIO): 49/100 — Mixed-negative evidence; evidence 83%
   - Growth & earnings 15.2/35 | Capital efficiency 15.8/25 | Valuation 11.8/20 | Relative strength 5.8/20
   - Price stage: TURNING — Ahead of the benchmark for one to four weeks, after a stretch of being behind.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 0 of the last 12 weeks
   - Exact sum: 15.2 + 15.8 + 11.8 + 5.8 = 48.6
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7. Krsnaa Diagnostics Ltd (KRSNAA): 43/100 — Mixed-negative evidence; evidence 77%
   - Growth & earnings 13.4/35 | Capital efficiency 10.5/25 | Valuation 14.6/20 | Relative strength 4.5/20
   - Price stage: ASLEEP — Neither ahead of the benchmark nor yet turning up against it.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 0 of 10 weeks with a reading, within the last 12
   - Exact sum: 13.4 + 10.5 + 14.6 + 4.5 = 43
   - Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
8. Suraksha Diagnostic Ltd (SURAKSHA): 39/100 — Mixed-negative evidence; evidence 76%
   - Growth & earnings 13.8/35 | Capital efficiency 13.0/25 | Valuation 10.4/20 | Relative strength 1.8/20
   - Price stage: ASLEEP — Neither ahead of the benchmark nor yet turning up against it.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 4 of the last 12 weeks
   - Exact sum: 13.8 + 13 + 10.4 + 1.8 = 39
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9. Vimta Labs Ltd (VIMTALABS): 44/100 — Thin evidence · provisional; evidence 45%
   - Growth & earnings 17.5/35 | Capital efficiency 13.5/25 | Valuation 7.5/20 | Relative strength 5.9/20
   - Price stage: TURNING — Ahead of the benchmark for one to four weeks, after a stretch of being behind.
   - Led NIFTY 500 by 5%+ over the prior 13 weeks in 7 of 10 weeks with a reading, within the last 12
   - Exact sum: 17.5 + 13.5 + 7.5 + 5.9 = 44.4
   - Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

## Market action

One Global Service Provider Ltd has the strongest one-year price move in Diagnostics at +121.4%. Thyrocare Technologies Ltd leads on Mansfield relative strength against NIFTY at +27.8%. 6 of 9 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-31.

### Strongest one-year price performers
1. One Global Service Provider Ltd (514330): 121%
2. Thyrocare Technologies Ltd (THYROCARE): 32%
3. Vijaya Diagnostic Centre Ltd (VIJAYA): 26%
4. Dr Lal Pathlabs Ltd (LALPATHLAB): 24%
5. Metropolis Healthcare Ltd (METROPOLIS): 18%

### Strongest relative strength versus NIFTY 500
1. Thyrocare Technologies Ltd (THYROCARE): 28%
2. Dr Lal Pathlabs Ltd (LALPATHLAB): 22%
3. Vijaya Diagnostic Centre Ltd (VIJAYA): 22%
4. Metropolis Healthcare Ltd (METROPOLIS): 14%
5. One Global Service Provider Ltd (514330): 11%

## Revenue Scale & Growth Durability

What the numbers say: Dr Lal Pathlabs Ltd is the scale leader at ₹2,892 crore, 75.7% ahead of Metropolis Healthcare Ltd. One Global Service Provider Ltd's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 311.6% from a ₹498 crore base, with 15 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

Investor read: Dr Lal Pathlabs Ltd is the scale benchmark; One Global Service Provider Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Dr Lal Pathlabs Ltd's growth falls below One Global Service Provider Ltd's for two consecutive comparable reports while operating margin also compresses.

Evidence: Dr Lal Pathlabs Ltd · ₹2,892 crore | 75.7% versus #2 · Metropolis Healthcare Ltd | 8/8 recent comparable periods | 9/9 companies · 145 observations

Definition: Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

### Revenue — largest
1. Dr Lal Pathlabs Ltd (LALPATHLAB): ₹2.9K Cr
2. Metropolis Healthcare Ltd (METROPOLIS): ₹1.6K Cr
3. Thyrocare Technologies Ltd (THYROCARE): ₹877 Cr
4. Vijaya Diagnostic Centre Ltd (VIJAYA): ₹814 Cr
5. Krsnaa Diagnostics Ltd (KRSNAA): ₹773 Cr

### Revenue growth — fastest growers
1. One Global Service Provider Ltd (514330): 100%
2. 3B Blackbio DX Ltd (3BBLACKBIO): 47%
3. Metropolis Healthcare Ltd (METROPOLIS): 24%
4. Suraksha Diagnostic Ltd (SURAKSHA): 23%
5. Thyrocare Technologies Ltd (THYROCARE): 21%

### 20-quarter Revenue history
- 514330: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 ₹3 Cr | Dec 2022 ₹8 Cr | Mar 2023 ₹5 Cr | Jun 2023 ₹13 Cr | Sep 2023 ₹12 Cr | Dec 2023 ₹15 Cr | Mar 2024 ₹24 Cr | Jun 2024 ₹14 Cr | Sep 2024 ₹19 Cr | Dec 2024 ₹33 Cr | Mar 2025 ₹55 Cr | Jun 2025 ₹88 Cr | Sep 2025 ₹135 Cr | Dec 2025 ₹141 Cr | Mar 2026 ₹134 Cr | Jun 2026 —
- LALPATHLAB: Sep 2021 ₹498 Cr | Dec 2021 ₹497 Cr | Mar 2022 ₹486 Cr | Jun 2022 ₹503 Cr | Sep 2022 ₹534 Cr | Dec 2022 ₹489 Cr | Mar 2023 ₹491 Cr | Jun 2023 ₹541 Cr | Sep 2023 ₹601 Cr | Dec 2023 ₹539 Cr | Mar 2024 ₹545 Cr | Jun 2024 ₹602 Cr | Sep 2024 ₹660 Cr | Dec 2024 ₹597 Cr | Mar 2025 ₹603 Cr | Jun 2025 ₹670 Cr | Sep 2025 ₹731 Cr | Dec 2025 ₹660 Cr | Mar 2026 ₹703 Cr | Jun 2026 ₹798 Cr
- VIJAYA: Sep 2021 ₹113 Cr | Dec 2021 ₹111 Cr | Mar 2022 ₹116 Cr | Jun 2022 ₹104 Cr | Sep 2022 ₹121 Cr | Dec 2022 ₹113 Cr | Mar 2023 ₹121 Cr | Jun 2023 ₹121 Cr | Sep 2023 ₹139 Cr | Dec 2023 ₹133 Cr | Mar 2024 ₹155 Cr | Jun 2024 ₹156 Cr | Sep 2024 ₹183 Cr | Dec 2024 ₹169 Cr | Mar 2025 ₹173 Cr | Jun 2025 ₹188 Cr | Sep 2025 ₹202 Cr | Dec 2025 ₹205 Cr | Mar 2026 ₹219 Cr | Jun 2026 —
- METROPOLIS: Sep 2021 ₹303 Cr | Dec 2021 ₹293 Cr | Mar 2022 ₹306 Cr | Jun 2022 ₹280 Cr | Sep 2022 ₹300 Cr | Dec 2022 ₹285 Cr | Mar 2023 ₹283 Cr | Jun 2023 ₹277 Cr | Sep 2023 ₹308 Cr | Dec 2023 ₹291 Cr | Mar 2024 ₹331 Cr | Jun 2024 ₹313 Cr | Sep 2024 ₹350 Cr | Dec 2024 ₹323 Cr | Mar 2025 ₹345 Cr | Jun 2025 ₹386 Cr | Sep 2025 ₹429 Cr | Dec 2025 ₹406 Cr | Mar 2026 ₹425 Cr | Jun 2026 —
- THYROCARE: Sep 2021 ₹176 Cr | Dec 2021 ₹117 Cr | Mar 2022 ₹131 Cr | Jun 2022 ₹128 Cr | Sep 2022 ₹135 Cr | Dec 2022 ₹128 Cr | Mar 2023 ₹136 Cr | Jun 2023 ₹135 Cr | Sep 2023 ₹148 Cr | Dec 2023 ₹135 Cr | Mar 2024 ₹154 Cr | Jun 2024 ₹157 Cr | Sep 2024 ₹177 Cr | Dec 2024 ₹166 Cr | Mar 2025 ₹187 Cr | Jun 2025 ₹193 Cr | Sep 2025 ₹217 Cr | Dec 2025 ₹196 Cr | Mar 2026 ₹224 Cr | Jun 2026 ₹240 Cr
- VIMTALABS: Sep 2021 — | Dec 2021 ₹67 Cr | Mar 2022 ₹74 Cr | Jun 2022 ₹79 Cr | Sep 2022 ₹80 Cr | Dec 2022 ₹77 Cr | Mar 2023 ₹82 Cr | Jun 2023 ₹83 Cr | Sep 2023 ₹66 Cr | Dec 2023 ₹75 Cr | Mar 2024 ₹80 Cr | Jun 2024 ₹75 Cr | Sep 2024 ₹85 Cr | Dec 2024 ₹90 Cr | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —
- KRSNAA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 ₹118 Cr | Mar 2023 ₹133 Cr | Jun 2023 ₹140 Cr | Sep 2023 ₹155 Cr | Dec 2023 ₹158 Cr | Mar 2024 ₹166 Cr | Jun 2024 ₹170 Cr | Sep 2024 ₹186 Cr | Dec 2024 ₹175 Cr | Mar 2025 ₹186 Cr | Jun 2025 ₹193 Cr | Sep 2025 ₹206 Cr | Dec 2025 ₹181 Cr | Mar 2026 ₹193 Cr | Jun 2026 —
- SURAKSHA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 ₹60 Cr | Dec 2023 ₹52 Cr | Mar 2024 ₹55 Cr | Jun 2024 ₹61 Cr | Sep 2024 ₹67 Cr | Dec 2024 ₹60 Cr | Mar 2025 ₹65 Cr | Jun 2025 ₹73 Cr | Sep 2025 ₹79 Cr | Dec 2025 ₹78 Cr | Mar 2026 ₹81 Cr | Jun 2026 —
- 3BBLACKBIO: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 ₹15 Cr | Mar 2023 ₹18 Cr | Jun 2023 ₹14 Cr | Sep 2023 ₹19 Cr | Dec 2023 ₹18 Cr | Mar 2024 ₹23 Cr | Jun 2024 ₹19 Cr | Sep 2024 ₹29 Cr | Dec 2024 ₹25 Cr | Mar 2025 ₹23 Cr | Jun 2025 ₹22 Cr | Sep 2025 ₹34 Cr | Dec 2025 ₹50 Cr | Mar 2026 ₹35 Cr | Jun 2026 —

### 20-quarter Revenue growth history
- 514330: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 300% | Dec 2023 88% | Mar 2024 380% | Jun 2024 7.7% | Sep 2024 58% | Dec 2024 120% | Mar 2025 129% | Jun 2025 529% | Sep 2025 611% | Dec 2025 327% | Mar 2026 144% | Jun 2026 —
- LALPATHLAB: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 -17% | Sep 2022 7.2% | Dec 2022 -1.6% | Mar 2023 1.0% | Jun 2023 7.6% | Sep 2023 13% | Dec 2023 10% | Mar 2024 11% | Jun 2024 11% | Sep 2024 9.8% | Dec 2024 11% | Mar 2025 11% | Jun 2025 11% | Sep 2025 11% | Dec 2025 11% | Mar 2026 17% | Jun 2026 19%
- VIJAYA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 -15% | Sep 2022 7.1% | Dec 2022 1.8% | Mar 2023 4.3% | Jun 2023 16% | Sep 2023 15% | Dec 2023 18% | Mar 2024 28% | Jun 2024 29% | Sep 2024 32% | Dec 2024 27% | Mar 2025 12% | Jun 2025 21% | Sep 2025 10% | Dec 2025 21% | Mar 2026 27% | Jun 2026 —
- METROPOLIS: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 -14% | Sep 2022 -1.0% | Dec 2022 -2.7% | Mar 2023 -7.5% | Jun 2023 -1.1% | Sep 2023 2.7% | Dec 2023 2.1% | Mar 2024 17% | Jun 2024 13% | Sep 2024 14% | Dec 2024 11% | Mar 2025 4.2% | Jun 2025 23% | Sep 2025 23% | Dec 2025 26% | Mar 2026 23% | Jun 2026 —
- THYROCARE: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 -22% | Sep 2022 -23% | Dec 2022 9.4% | Mar 2023 3.8% | Jun 2023 5.5% | Sep 2023 9.6% | Dec 2023 5.5% | Mar 2024 13% | Jun 2024 16% | Sep 2024 20% | Dec 2024 23% | Mar 2025 21% | Jun 2025 23% | Sep 2025 23% | Dec 2025 18% | Mar 2026 20% | Jun 2026 24%
- VIMTALABS: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 15% | Mar 2023 11% | Jun 2023 5.1% | Sep 2023 -18% | Dec 2023 -2.6% | Mar 2024 -2.4% | Jun 2024 -9.6% | Sep 2024 29% | Dec 2024 20% | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —
- KRSNAA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 34% | Mar 2024 25% | Jun 2024 21% | Sep 2024 20% | Dec 2024 11% | Mar 2025 12% | Jun 2025 14% | Sep 2025 11% | Dec 2025 3.4% | Mar 2026 3.8% | Jun 2026 —
- SURAKSHA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 11% | Dec 2024 15% | Mar 2025 18% | Jun 2025 20% | Sep 2025 18% | Dec 2025 31% | Mar 2026 25% | Jun 2026 —
- 3BBLACKBIO: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 18% | Mar 2024 27% | Jun 2024 36% | Sep 2024 52% | Dec 2024 44% | Mar 2025 -2.2% | Jun 2025 14% | Sep 2025 16% | Dec 2025 98% | Mar 2026 57% | Jun 2026 —

## Operating Economics & Margin Trend

What the numbers say: Vijaya Diagnostic Centre Ltd leads opm at 44%; Metropolis Healthcare Ltd leads margin change at +7 percentage points.

Investor read: Vijaya Diagnostic Centre Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Evidence: Vijaya Diagnostic Centre Ltd · 44% | 18.9% versus #2 · Vimta Labs Ltd | 4/8 recent comparable periods | 9/9 companies · 160 observations

Definition: Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

### OPM — highest
1. Vijaya Diagnostic Centre Ltd (VIJAYA): 44%
2. Vimta Labs Ltd (VIMTALABS): 37% — older report
3. Thyrocare Technologies Ltd (THYROCARE): 32%
4. Dr Lal Pathlabs Ltd (LALPATHLAB): 31%
5. Suraksha Diagnostic Ltd (SURAKSHA): 30%

### Margin change — fastest expanders
1. Metropolis Healthcare Ltd (METROPOLIS): +7.0 pp
2. Vimta Labs Ltd (VIMTALABS): +5.0 pp — older report
3. Vijaya Diagnostic Centre Ltd (VIJAYA): +4.0 pp
4. Dr Lal Pathlabs Ltd (LALPATHLAB): +2.0 pp
5. Thyrocare Technologies Ltd (THYROCARE): +2.0 pp

### 20-quarter OPM history
- 514330: Sep 2021 21% | Dec 2021 32% | Mar 2022 33% | Jun 2022 9.1% | Sep 2022 9.0% | Dec 2022 9.0% | Mar 2023 10% | Jun 2023 11% | Sep 2023 8.0% | Dec 2023 14% | Mar 2024 22% | Jun 2024 17% | Sep 2024 16% | Dec 2024 14% | Mar 2025 26% | Jun 2025 15% | Sep 2025 19% | Dec 2025 21% | Mar 2026 18% | Jun 2026 —
- LALPATHLAB: Sep 2021 28% | Dec 2021 22% | Mar 2022 25% | Jun 2022 23% | Sep 2022 27% | Dec 2022 23% | Mar 2023 24% | Jun 2023 27% | Sep 2023 30% | Dec 2023 26% | Mar 2024 27% | Jun 2024 28% | Sep 2024 31% | Dec 2024 26% | Mar 2025 28% | Jun 2025 29% | Sep 2025 31% | Dec 2025 27% | Mar 2026 27% | Jun 2026 31%
- VIJAYA: Sep 2021 45% | Dec 2021 43% | Mar 2022 41% | Jun 2022 38% | Sep 2022 40% | Dec 2022 39% | Mar 2023 41% | Jun 2023 40% | Sep 2023 41% | Dec 2023 39% | Mar 2024 41% | Jun 2024 39% | Sep 2024 42% | Dec 2024 40% | Mar 2025 40% | Jun 2025 39% | Sep 2025 41% | Dec 2025 42% | Mar 2026 44% | Jun 2026 —
- METROPOLIS: Sep 2021 30% | Dec 2021 26% | Mar 2022 24% | Jun 2022 24% | Sep 2022 26% | Dec 2022 25% | Mar 2023 25% | Jun 2023 23% | Sep 2023 24% | Dec 2023 22% | Mar 2024 24% | Jun 2024 25% | Sep 2024 26% | Dec 2024 22% | Mar 2025 18% | Jun 2025 23% | Sep 2025 25% | Dec 2025 23% | Mar 2026 25% | Jun 2026 —
- THYROCARE: Sep 2021 51% | Dec 2021 31% | Mar 2022 29% | Jun 2022 28% | Sep 2022 23% | Dec 2022 22% | Mar 2023 18% | Jun 2023 26% | Sep 2023 25% | Dec 2023 23% | Mar 2024 22% | Jun 2024 27% | Sep 2024 27% | Dec 2024 25% | Mar 2025 30% | Jun 2025 30% | Sep 2025 33% | Dec 2025 30% | Mar 2026 34% | Jun 2026 32%
- VIMTALABS: Sep 2021 26% | Dec 2021 31% | Mar 2022 31% | Jun 2022 30% | Sep 2022 32% | Dec 2022 28% | Mar 2023 30% | Jun 2023 30% | Sep 2023 27% | Dec 2023 32% | Mar 2024 31% | Jun 2024 35% | Sep 2024 35% | Dec 2024 37% | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —
- KRSNAA: Sep 2021 29% | Dec 2021 28% | Mar 2022 26% | Jun 2022 25% | Sep 2022 25% | Dec 2022 25% | Mar 2023 26% | Jun 2023 22% | Sep 2023 20% | Dec 2023 24% | Mar 2024 26% | Jun 2024 25% | Sep 2024 27% | Dec 2024 26% | Mar 2025 28% | Jun 2025 27% | Sep 2025 29% | Dec 2025 26% | Mar 2026 28% | Jun 2026 —
- SURAKSHA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 35% | Dec 2023 30% | Mar 2024 35% | Jun 2024 34% | Sep 2024 35% | Dec 2024 31% | Mar 2025 29% | Jun 2025 33% | Sep 2025 31% | Dec 2025 30% | Mar 2026 30% | Jun 2026 —
- 3BBLACKBIO: Sep 2021 39% | Dec 2021 49% | Mar 2022 32% | Jun 2022 44% | Sep 2022 53% | Dec 2022 50% | Mar 2023 41% | Jun 2023 45% | Sep 2023 41% | Dec 2023 50% | Mar 2024 43% | Jun 2024 56% | Sep 2024 55% | Dec 2024 59% | Mar 2025 35% | Jun 2025 53% | Sep 2025 43% | Dec 2025 43% | Mar 2026 24% | Jun 2026 —

### 20-quarter Margin change history
- 514330: Sep 2021 −75.7 pp | Dec 2021 −32.1 pp | Mar 2022 −29.0 pp | Jun 2022 −0.8 pp | Sep 2022 −12.0 pp | Dec 2022 −23.4 pp | Mar 2023 −22.8 pp | Jun 2023 +1.9 pp | Sep 2023 −1.0 pp | Dec 2023 +5.0 pp | Mar 2024 +12.0 pp | Jun 2024 +6.0 pp | Sep 2024 +8.0 pp | Dec 2024 0.0 pp | Mar 2025 +4.0 pp | Jun 2025 −2.0 pp | Sep 2025 +3.0 pp | Dec 2025 +7.0 pp | Mar 2026 −8.0 pp | Jun 2026 —
- LALPATHLAB: Sep 2021 −1.1 pp | Dec 2021 −8.7 pp | Mar 2022 −3.4 pp | Jun 2022 −7.8 pp | Sep 2022 −1.5 pp | Dec 2022 +1.0 pp | Mar 2023 −0.9 pp | Jun 2023 +3.6 pp | Sep 2023 +3.1 pp | Dec 2023 +3.0 pp | Mar 2024 +3.0 pp | Jun 2024 +1.0 pp | Sep 2024 +1.0 pp | Dec 2024 0.0 pp | Mar 2025 +1.0 pp | Jun 2025 +1.0 pp | Sep 2025 0.0 pp | Dec 2025 +1.0 pp | Mar 2026 −1.0 pp | Jun 2026 +2.0 pp
- VIJAYA: Sep 2021 +0.1 pp | Dec 2021 −3.3 pp | Mar 2022 −7.4 pp | Jun 2022 −8.1 pp | Sep 2022 −5.0 pp | Dec 2022 −4.2 pp | Mar 2023 −0.2 pp | Jun 2023 +1.8 pp | Sep 2023 +0.6 pp | Dec 2023 0.0 pp | Mar 2024 0.0 pp | Jun 2024 −1.0 pp | Sep 2024 +1.0 pp | Dec 2024 +1.0 pp | Mar 2025 −1.0 pp | Jun 2025 0.0 pp | Sep 2025 −1.0 pp | Dec 2025 +2.0 pp | Mar 2026 +4.0 pp | Jun 2026 —
- METROPOLIS: Sep 2021 −1.7 pp | Dec 2021 −5.8 pp | Mar 2022 −8.6 pp | Jun 2022 −6.9 pp | Sep 2022 −3.5 pp | Dec 2022 −0.7 pp | Mar 2023 +0.5 pp | Jun 2023 −1.5 pp | Sep 2023 −2.3 pp | Dec 2023 −3.0 pp | Mar 2024 −1.0 pp | Jun 2024 +2.0 pp | Sep 2024 +2.0 pp | Dec 2024 0.0 pp | Mar 2025 −6.0 pp | Jun 2025 −2.0 pp | Sep 2025 −1.0 pp | Dec 2025 +1.0 pp | Mar 2026 +7.0 pp | Jun 2026 —
- THYROCARE: Sep 2021 +10.2 pp | Dec 2021 −4.7 pp | Mar 2022 −6.3 pp | Jun 2022 −15.0 pp | Sep 2022 −27.2 pp | Dec 2022 −9.2 pp | Mar 2023 −10.8 pp | Jun 2023 −2.1 pp | Sep 2023 +1.6 pp | Dec 2023 +1.0 pp | Mar 2024 +4.0 pp | Jun 2024 +1.0 pp | Sep 2024 +2.0 pp | Dec 2024 +2.0 pp | Mar 2025 +8.0 pp | Jun 2025 +3.0 pp | Sep 2025 +6.0 pp | Dec 2025 +5.0 pp | Mar 2026 +4.0 pp | Jun 2026 +2.0 pp
- VIMTALABS: Sep 2021 −0.5 pp | Dec 2021 +2.6 pp | Mar 2022 +3.1 pp | Jun 2022 +2.8 pp | Sep 2022 +5.6 pp | Dec 2022 −3.0 pp | Mar 2023 −1.0 pp | Jun 2023 0.0 pp | Sep 2023 −5.0 pp | Dec 2023 +4.0 pp | Mar 2024 +1.0 pp | Jun 2024 +5.0 pp | Sep 2024 +8.0 pp | Dec 2024 +5.0 pp | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —
- KRSNAA: Sep 2021 +1.0 pp | Dec 2021 +9.1 pp | Mar 2022 −8.8 pp | Jun 2022 −6.7 pp | Sep 2022 −4.6 pp | Dec 2022 −3.2 pp | Mar 2023 +0.1 pp | Jun 2023 −2.6 pp | Sep 2023 −4.9 pp | Dec 2023 −1.0 pp | Mar 2024 0.0 pp | Jun 2024 +3.0 pp | Sep 2024 +7.0 pp | Dec 2024 +2.0 pp | Mar 2025 +2.0 pp | Jun 2025 +2.0 pp | Sep 2025 +2.0 pp | Dec 2025 0.0 pp | Mar 2026 0.0 pp | Jun 2026 —
- SURAKSHA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 +0.1 pp | Dec 2024 +1.1 pp | Mar 2025 −5.8 pp | Jun 2025 −1.2 pp | Sep 2025 −4.1 pp | Dec 2025 −0.9 pp | Mar 2026 +0.5 pp | Jun 2026 —
- 3BBLACKBIO: Sep 2021 −31.7 pp | Dec 2021 −10.0 pp | Mar 2022 −12.9 pp | Jun 2022 −11.4 pp | Sep 2022 +13.6 pp | Dec 2022 +1.5 pp | Mar 2023 +9.0 pp | Jun 2023 +0.8 pp | Sep 2023 −12.4 pp | Dec 2023 +0.2 pp | Mar 2024 +1.8 pp | Jun 2024 +11.3 pp | Sep 2024 +14.9 pp | Dec 2024 +9.2 pp | Mar 2025 −7.8 pp | Jun 2025 −3.1 pp | Sep 2025 −12.0 pp | Dec 2025 −16.2 pp | Mar 2026 −11.2 pp | Jun 2026 —

## Profit Scale & Acceleration

What the numbers say: Dr Lal Pathlabs Ltd leads with ₹545 crore of TTM profit, 185.3% above Metropolis Healthcare Ltd. One Global Service Provider Ltd shows ≥100% on the scoring scale (288.9% uncapped) growth from a ₹70 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

Investor read: Dr Lal Pathlabs Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Evidence: Dr Lal Pathlabs Ltd · ₹545 crore | 185.3% versus #2 · Metropolis Healthcare Ltd | 6/8 recent comparable periods | 9/9 companies · 145 observations

Definition: Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

### Net profit — largest
1. Dr Lal Pathlabs Ltd (LALPATHLAB): ₹545 Cr
2. Metropolis Healthcare Ltd (METROPOLIS): ₹191 Cr
3. Thyrocare Technologies Ltd (THYROCARE): ₹176 Cr
4. Vijaya Diagnostic Centre Ltd (VIJAYA): ₹173 Cr
5. Krsnaa Diagnostics Ltd (KRSNAA): ₹102 Cr

### Profit growth — fastest growers
1. One Global Service Provider Ltd (514330): 100%
2. Thyrocare Technologies Ltd (THYROCARE): 68%
3. Vimta Labs Ltd (VIMTALABS): 49% — older report
4. Metropolis Healthcare Ltd (METROPOLIS): 32%
5. Krsnaa Diagnostics Ltd (KRSNAA): 31%

### 20-quarter Net profit history
- 514330: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 ₹0 Cr | Dec 2022 ₹1 Cr | Mar 2023 ₹0 Cr | Jun 2023 ₹1 Cr | Sep 2023 ₹1 Cr | Dec 2023 ₹1 Cr | Mar 2024 ₹4 Cr | Jun 2024 ₹2 Cr | Sep 2024 ₹2 Cr | Dec 2024 ₹3 Cr | Mar 2025 ₹11 Cr | Jun 2025 ₹10 Cr | Sep 2025 ₹20 Cr | Dec 2025 ₹22 Cr | Mar 2026 ₹18 Cr | Jun 2026 —
- LALPATHLAB: Sep 2021 ₹95 Cr | Dec 2021 ₹57 Cr | Mar 2022 ₹61 Cr | Jun 2022 ₹58 Cr | Sep 2022 ₹72 Cr | Dec 2022 ₹54 Cr | Mar 2023 ₹57 Cr | Jun 2023 ₹84 Cr | Sep 2023 ₹111 Cr | Dec 2023 ₹82 Cr | Mar 2024 ₹86 Cr | Jun 2024 ₹108 Cr | Sep 2024 ₹131 Cr | Dec 2024 ₹98 Cr | Mar 2025 ₹156 Cr | Jun 2025 ₹134 Cr | Sep 2025 ₹152 Cr | Dec 2025 ₹91 Cr | Mar 2026 ₹132 Cr | Jun 2026 ₹170 Cr
- VIJAYA: Sep 2021 ₹28 Cr | Dec 2021 ₹25 Cr | Mar 2022 ₹24 Cr | Jun 2022 ₹17 Cr | Sep 2022 ₹23 Cr | Dec 2022 ₹16 Cr | Mar 2023 ₹28 Cr | Jun 2023 ₹26 Cr | Sep 2023 ₹34 Cr | Dec 2023 ₹26 Cr | Mar 2024 ₹34 Cr | Jun 2024 ₹32 Cr | Sep 2024 ₹42 Cr | Dec 2024 ₹35 Cr | Mar 2025 ₹35 Cr | Jun 2025 ₹39 Cr | Sep 2025 ₹43 Cr | Dec 2025 ₹43 Cr | Mar 2026 ₹48 Cr | Jun 2026 —
- METROPOLIS: Sep 2021 ₹58 Cr | Dec 2021 ₹41 Cr | Mar 2022 ₹40 Cr | Jun 2022 ₹33 Cr | Sep 2022 ₹40 Cr | Dec 2022 ₹36 Cr | Mar 2023 ₹33 Cr | Jun 2023 ₹29 Cr | Sep 2023 ₹36 Cr | Dec 2023 ₹27 Cr | Mar 2024 ₹37 Cr | Jun 2024 ₹38 Cr | Sep 2024 ₹47 Cr | Dec 2024 ₹31 Cr | Mar 2025 ₹29 Cr | Jun 2025 ₹45 Cr | Sep 2025 ₹53 Cr | Dec 2025 ₹42 Cr | Mar 2026 ₹51 Cr | Jun 2026 —
- THYROCARE: Sep 2021 ₹78 Cr | Dec 2021 ₹22 Cr | Mar 2022 ₹21 Cr | Jun 2022 ₹22 Cr | Sep 2022 ₹15 Cr | Dec 2022 ₹15 Cr | Mar 2023 ₹12 Cr | Jun 2023 ₹17 Cr | Sep 2023 ₹20 Cr | Dec 2023 ₹15 Cr | Mar 2024 ₹17 Cr | Jun 2024 ₹24 Cr | Sep 2024 ₹26 Cr | Dec 2024 ₹19 Cr | Mar 2025 ₹22 Cr | Jun 2025 ₹38 Cr | Sep 2025 ₹48 Cr | Dec 2025 ₹28 Cr | Mar 2026 ₹49 Cr | Jun 2026 ₹51 Cr
- VIMTALABS: Sep 2021 — | Dec 2021 ₹12 Cr | Mar 2022 ₹12 Cr | Jun 2022 ₹12 Cr | Sep 2022 ₹13 Cr | Dec 2022 ₹10 Cr | Mar 2023 ₹13 Cr | Jun 2023 ₹12 Cr | Sep 2023 ₹6 Cr | Dec 2023 ₹10 Cr | Mar 2024 ₹12 Cr | Jun 2024 ₹12 Cr | Sep 2024 ₹15 Cr | Dec 2024 ₹22 Cr | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —
- KRSNAA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 ₹14 Cr | Mar 2023 ₹19 Cr | Jun 2023 ₹15 Cr | Sep 2023 ₹10 Cr | Dec 2023 ₹13 Cr | Mar 2024 ₹19 Cr | Jun 2024 ₹18 Cr | Sep 2024 ₹20 Cr | Dec 2024 ₹19 Cr | Mar 2025 ₹21 Cr | Jun 2025 ₹21 Cr | Sep 2025 ₹24 Cr | Dec 2025 ₹15 Cr | Mar 2026 ₹42 Cr | Jun 2026 —
- SURAKSHA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 ₹8 Cr | Dec 2023 ₹5 Cr | Mar 2024 ₹6 Cr | Jun 2024 ₹8 Cr | Sep 2024 ₹10 Cr | Dec 2024 ₹6 Cr | Mar 2025 ₹7 Cr | Jun 2025 ₹9 Cr | Sep 2025 ₹9 Cr | Dec 2025 ₹7 Cr | Mar 2026 ₹6 Cr | Jun 2026 —
- 3BBLACKBIO: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 ₹8 Cr | Mar 2023 ₹5 Cr | Jun 2023 ₹7 Cr | Sep 2023 ₹8 Cr | Dec 2023 ₹9 Cr | Mar 2024 ₹9 Cr | Jun 2024 ₹11 Cr | Sep 2024 ₹15 Cr | Dec 2024 ₹13 Cr | Mar 2025 ₹8 Cr | Jun 2025 ₹13 Cr | Sep 2025 ₹15 Cr | Dec 2025 ₹22 Cr | Mar 2026 ₹10 Cr | Jun 2026 —

### 20-quarter Profit growth history
- 514330: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 0.0% | Mar 2024 — | Jun 2024 100% | Sep 2024 100% | Dec 2024 200% | Mar 2025 175% | Jun 2025 400% | Sep 2025 900% | Dec 2025 633% | Mar 2026 64% | Jun 2026 —
- LALPATHLAB: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 -56% | Sep 2022 -24% | Dec 2022 -5.3% | Mar 2023 -6.6% | Jun 2023 45% | Sep 2023 54% | Dec 2023 52% | Mar 2024 51% | Jun 2024 29% | Sep 2024 18% | Dec 2024 20% | Mar 2025 81% | Jun 2025 24% | Sep 2025 16% | Dec 2025 -7.1% | Mar 2026 -15% | Jun 2026 27%
- VIJAYA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 -48% | Sep 2022 -18% | Dec 2022 -36% | Mar 2023 17% | Jun 2023 53% | Sep 2023 48% | Dec 2023 63% | Mar 2024 21% | Jun 2024 23% | Sep 2024 24% | Dec 2024 35% | Mar 2025 2.9% | Jun 2025 22% | Sep 2025 2.4% | Dec 2025 23% | Mar 2026 37% | Jun 2026 —
- METROPOLIS: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 -56% | Sep 2022 -31% | Dec 2022 -12% | Mar 2023 -18% | Jun 2023 -12% | Sep 2023 -10% | Dec 2023 -25% | Mar 2024 12% | Jun 2024 31% | Sep 2024 31% | Dec 2024 15% | Mar 2025 -22% | Jun 2025 18% | Sep 2025 13% | Dec 2025 35% | Mar 2026 76% | Jun 2026 —
- THYROCARE: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 -61% | Sep 2022 -81% | Dec 2022 -32% | Mar 2023 -43% | Jun 2023 -23% | Sep 2023 33% | Dec 2023 0.0% | Mar 2024 42% | Jun 2024 41% | Sep 2024 30% | Dec 2024 27% | Mar 2025 29% | Jun 2025 58% | Sep 2025 85% | Dec 2025 47% | Mar 2026 123% | Jun 2026 34%
- VIMTALABS: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 -17% | Mar 2023 8.3% | Jun 2023 0.0% | Sep 2023 -54% | Dec 2023 0.0% | Mar 2024 -7.7% | Jun 2024 0.0% | Sep 2024 150% | Dec 2024 120% | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —
- KRSNAA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 -7.1% | Mar 2024 0.0% | Jun 2024 20% | Sep 2024 100% | Dec 2024 46% | Mar 2025 11% | Jun 2025 17% | Sep 2025 20% | Dec 2025 -21% | Mar 2026 100% | Jun 2026 —
- SURAKSHA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 22% | Dec 2024 32% | Mar 2025 13% | Jun 2025 20% | Sep 2025 -13% | Dec 2025 21% | Mar 2026 -14% | Jun 2026 —
- 3BBLACKBIO: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 6.4% | Mar 2024 69% | Jun 2024 57% | Sep 2024 96% | Dec 2024 59% | Mar 2025 -8.5% | Jun 2025 12% | Sep 2025 1.1% | Dec 2025 66% | Mar 2026 22% | Jun 2026 —

## Return On Capital Employed

What the numbers say: One Global Service Provider Ltd leads ROCE at 87%, 51.6 percentage points above Thyrocare Technologies Ltd. One Global Service Provider Ltd has the strongest latest improvement at +31 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

Investor read: One Global Service Provider Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

Evidence: One Global Service Provider Ltd · 87% | 145.8% versus #2 · Thyrocare Technologies Ltd | Not enough history | 9/9 companies · 101 observations

Definition: ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

### ROCE — highest
1. One Global Service Provider Ltd (514330): 87%
2. Thyrocare Technologies Ltd (THYROCARE): 35%
3. Dr Lal Pathlabs Ltd (LALPATHLAB): 28%
4. 3B Blackbio DX Ltd (3BBLACKBIO): 26%
5. Vijaya Diagnostic Centre Ltd (VIJAYA): 21%

### ROCE change — fastest improvers
1. One Global Service Provider Ltd (514330): +31.0 pp
2. Thyrocare Technologies Ltd (THYROCARE): +8.3 pp
3. Metropolis Healthcare Ltd (METROPOLIS): +2.4 pp
4. Vijaya Diagnostic Centre Ltd (VIJAYA): −0.5 pp
5. Dr Lal Pathlabs Ltd (LALPATHLAB): −1.0 pp

### 20-quarter ROCE history
- LALPATHLAB: Sep 2021 34% | Dec 2021 — | Mar 2022 25% | Jun 2022 — | Sep 2022 19% | Dec 2022 — | Mar 2023 18% | Jun 2023 — | Sep 2023 21% | Dec 2023 26% | Mar 2024 24% | Jun 2024 29% | Sep 2024 24% | Dec 2024 30% | Mar 2025 24% | Jun 2025 31% | Sep 2025 24% | Dec 2025 29% | Mar 2026 23% | Jun 2026 —
- VIJAYA: Sep 2021 27% | Dec 2021 — | Mar 2022 23% | Jun 2022 — | Sep 2022 17% | Dec 2022 — | Mar 2023 15% | Jun 2023 — | Sep 2023 17% | Dec 2023 22% | Mar 2024 18% | Jun 2024 22% | Sep 2024 19% | Dec 2024 23% | Mar 2025 18% | Jun 2025 23% | Sep 2025 17% | Dec 2025 22% | Mar 2026 18% | Jun 2026 —
- METROPOLIS: Sep 2021 34% | Dec 2021 — | Mar 2022 23% | Jun 2022 — | Sep 2022 18% | Dec 2022 — | Mar 2023 17% | Jun 2023 — | Sep 2023 15% | Dec 2023 15% | Mar 2024 15% | Jun 2024 16% | Sep 2024 16% | Dec 2024 17% | Mar 2025 12% | Jun 2025 15% | Sep 2025 13% | Dec 2025 16% | Mar 2026 15% | Jun 2026 —
- THYROCARE: Sep 2021 45% | Dec 2021 41% | Mar 2022 37% | Jun 2022 — | Sep 2022 21% | Dec 2022 18% | Mar 2023 15% | Jun 2023 — | Sep 2023 16% | Dec 2023 18% | Mar 2024 17% | Jun 2024 20% | Sep 2024 21% | Dec 2024 25% | Mar 2025 24% | Jun 2025 30% | Sep 2025 31% | Dec 2025 37% | Mar 2026 32% | Jun 2026 —
- KRSNAA: Sep 2021 12% | Dec 2021 — | Mar 2022 12% | Jun 2022 — | Sep 2022 9.4% | Dec 2022 — | Mar 2023 8.5% | Jun 2023 — | Sep 2023 7.7% | Dec 2023 10% | Mar 2024 7.8% | Jun 2024 11% | Sep 2024 9.9% | Dec 2024 14% | Mar 2025 10% | Jun 2025 14% | Sep 2025 11% | Dec 2025 14% | Mar 2026 7.8% | Jun 2026 —
- SURAKSHA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 16% | Jun 2024 17% | Sep 2024 17% | Dec 2024 18% | Mar 2025 16% | Jun 2025 19% | Sep 2025 14% | Dec 2025 18% | Mar 2026 14% | Jun 2026 —
- 3BBLACKBIO: Sep 2021 39% | Dec 2021 — | Mar 2022 25% | Jun 2022 — | Sep 2022 18% | Dec 2022 — | Mar 2023 15% | Jun 2023 — | Sep 2023 12% | Dec 2023 19% | Mar 2024 14% | Jun 2024 23% | Sep 2024 18% | Dec 2024 28% | Mar 2025 18% | Jun 2025 26% | Sep 2025 15% | Dec 2025 26% | Mar 2026 15% | Jun 2026 —

### 20-quarter ROCE change history
- LALPATHLAB: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −14.8 pp | Dec 2022 — | Mar 2023 −6.8 pp | Jun 2023 — | Sep 2023 +1.7 pp | Dec 2023 — | Mar 2024 +5.7 pp | Jun 2024 — | Sep 2024 +3.6 pp | Dec 2024 +3.7 pp | Mar 2025 +0.7 pp | Jun 2025 +2.4 pp | Sep 2025 −0.5 pp | Dec 2025 −0.6 pp | Mar 2026 −1.0 pp | Jun 2026 —
- VIJAYA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −10.0 pp | Dec 2022 — | Mar 2023 −8.0 pp | Jun 2023 — | Sep 2023 −0.7 pp | Dec 2023 — | Mar 2024 +2.7 pp | Jun 2024 — | Sep 2024 +2.1 pp | Dec 2024 +0.9 pp | Mar 2025 +0.2 pp | Jun 2025 +0.4 pp | Sep 2025 −1.5 pp | Dec 2025 −1.2 pp | Mar 2026 −0.5 pp | Jun 2026 —
- METROPOLIS: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −16.2 pp | Dec 2022 — | Mar 2023 −6.4 pp | Jun 2023 — | Sep 2023 −2.8 pp | Dec 2023 — | Mar 2024 −1.6 pp | Jun 2024 — | Sep 2024 +0.2 pp | Dec 2024 +1.7 pp | Mar 2025 −2.5 pp | Jun 2025 −1.1 pp | Sep 2025 −2.9 pp | Dec 2025 −1.0 pp | Mar 2026 +2.4 pp | Jun 2026 —
- THYROCARE: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −24.0 pp | Dec 2022 −23.1 pp | Mar 2023 −22.2 pp | Jun 2023 — | Sep 2023 −4.8 pp | Dec 2023 −0.2 pp | Mar 2024 +1.8 pp | Jun 2024 — | Sep 2024 +5.1 pp | Dec 2024 +6.8 pp | Mar 2025 +7.1 pp | Jun 2025 +9.9 pp | Sep 2025 +10.1 pp | Dec 2025 +12.8 pp | Mar 2026 +8.3 pp | Jun 2026 —
- KRSNAA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −2.8 pp | Dec 2022 — | Mar 2023 −3.5 pp | Jun 2023 — | Sep 2023 −1.7 pp | Dec 2023 — | Mar 2024 −0.7 pp | Jun 2024 — | Sep 2024 +2.2 pp | Dec 2024 +3.4 pp | Mar 2025 +2.6 pp | Jun 2025 +3.0 pp | Sep 2025 +0.9 pp | Dec 2025 −0.1 pp | Mar 2026 −2.6 pp | Jun 2026 —
- SURAKSHA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 −0.1 pp | Jun 2025 +2.2 pp | Sep 2025 −2.6 pp | Dec 2025 −0.3 pp | Mar 2026 −2.1 pp | Jun 2026 —
- 3BBLACKBIO: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 −21.0 pp | Dec 2022 — | Mar 2023 −10.2 pp | Jun 2023 — | Sep 2023 −5.8 pp | Dec 2023 — | Mar 2024 −0.4 pp | Jun 2024 — | Sep 2024 +5.8 pp | Dec 2024 +8.4 pp | Mar 2025 +3.7 pp | Jun 2025 +2.8 pp | Sep 2025 −2.3 pp | Dec 2025 −1.5 pp | Mar 2026 −2.6 pp | Jun 2026 —

## Valuation Against Growth & Quality

What the numbers say: Thyrocare Technologies Ltd has the lowest comparable PEG at 1.1×, 14.7% below Dr Lal Pathlabs Ltd. Only 4 of 9 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

Evidence: Thyrocare Technologies Ltd · 1.1× | 14.7% versus #2 · Dr Lal Pathlabs Ltd | 0/8 recent comparable periods | 4/9 companies · 33 observations

Definition: PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

### PEG — lowest PEG
1. Thyrocare Technologies Ltd (THYROCARE): 1.1
2. Dr Lal Pathlabs Ltd (LALPATHLAB): 1.3
3. Vijaya Diagnostic Centre Ltd (VIJAYA): 1.5
4. Metropolis Healthcare Ltd (METROPOLIS): 2.4

### P/E — lowest P/E
1. One Global Service Provider Ltd (514330): 15.9
2. Krsnaa Diagnostics Ltd (KRSNAA): 16.9
3. 3B Blackbio DX Ltd (3BBLACKBIO): 18.3
4. Suraksha Diagnostic Ltd (SURAKSHA): 40.8
5. Vimta Labs Ltd (VIMTALABS): 44.8 — older report

### 20-quarter PEG history
- LALPATHLAB: Sep 2021 2.8 | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 3.3 | Mar 2024 1.6 | Jun 2024 1.3 | Sep 2024 1.6 | Dec 2024 1.9 | Mar 2025 1.9 | Jun 2025 1.4 | Sep 2025 1.5 | Dec 2025 — | Mar 2026 1.3 | Jun 2026 —
- VIJAYA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 3.0 | Jun 2023 — | Sep 2023 — | Dec 2023 4.5 | Mar 2024 1.4 | Jun 2024 1.5 | Sep 2024 2.1 | Dec 2024 2.8 | Mar 2025 3.1 | Jun 2025 3.6 | Sep 2025 3.4 | Dec 2025 5.2 | Mar 2026 1.5 | Jun 2026 —
- METROPOLIS: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 3.5 | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 7.7 | Jun 2024 — | Sep 2024 — | Dec 2024 4.7 | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 2.4 | Mar 2026 — | Jun 2026 —
- THYROCARE: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 1.0 | Jun 2024 4.8 | Sep 2024 1.9 | Dec 2024 2.0 | Mar 2025 1.2 | Jun 2025 2.0 | Sep 2025 1.5 | Dec 2025 1.1 | Mar 2026 — | Jun 2026 —

### 20-quarter P/E history
- 514330: Sep 2021 5.6 | Dec 2021 7.4 | Mar 2022 17.8 | Jun 2022 32.5 | Sep 2022 22.5 | Dec 2022 20.9 | Mar 2023 13.0 | Jun 2023 16.6 | Sep 2023 15.9 | Dec 2023 10.8 | Mar 2024 15.6 | Jun 2024 14.3 | Sep 2024 16.2 | Dec 2024 25.9 | Mar 2025 22.9 | Jun 2025 14.2 | Sep 2025 10.7 | Dec 2025 24.3 | Mar 2026 20.0 | Jun 2026 —
- LALPATHLAB: Sep 2021 82.2 | Dec 2021 78.8 | Mar 2022 59.9 | Jun 2022 49.0 | Sep 2022 77.4 | Dec 2022 76.0 | Mar 2023 62.6 | Jun 2023 78.8 | Sep 2023 79.8 | Dec 2023 71.3 | Mar 2024 57.2 | Jun 2024 64.9 | Sep 2024 71.6 | Dec 2024 61.4 | Mar 2025 49.7 | Jun 2025 47.9 | Sep 2025 52.1 | Dec 2025 44.0 | Mar 2026 40.5 | Jun 2026 53.9
- VIJAYA: Sep 2021 31.2 | Dec 2021 31.3 | Mar 2022 23.6 | Jun 2022 30.8 | Sep 2022 49.9 | Dec 2022 49.7 | Mar 2023 49.4 | Jun 2023 57.0 | Sep 2023 54.6 | Dec 2023 66.8 | Mar 2024 56.9 | Jun 2024 63.6 | Sep 2024 71.8 | Dec 2024 82.0 | Mar 2025 72.7 | Jun 2025 70.4 | Sep 2025 69.1 | Dec 2025 69.6 | Mar 2026 55.6 | Jun 2026 —
- METROPOLIS: Sep 2021 64.1 | Dec 2021 72.8 | Mar 2022 45.5 | Jun 2022 36.4 | Sep 2022 46.0 | Dec 2022 43.9 | Mar 2023 42.8 | Jun 2023 53.5 | Sep 2023 54.1 | Dec 2023 64.5 | Mar 2024 70.8 | Jun 2024 79.2 | Sep 2024 81.7 | Dec 2024 71.3 | Mar 2025 54.2 | Jun 2025 68.2 | Sep 2025 76.5 | Dec 2025 72.9 | Mar 2026 51.0 | Jun 2026 —
- THYROCARE: Sep 2021 39.8 | Dec 2021 28.8 | Mar 2022 21.4 | Jun 2022 18.9 | Sep 2022 26.1 | Dec 2022 41.0 | Mar 2023 31.1 | Jun 2023 42.5 | Sep 2023 50.1 | Dec 2023 52.5 | Mar 2024 47.6 | Jun 2024 47.6 | Sep 2024 55.7 | Dec 2024 58.5 | Mar 2025 41.0 | Jun 2025 57.6 | Sep 2025 56.0 | Dec 2025 57.4 | Mar 2026 40.5 | Jun 2026 51.2
- VIMTALABS: Sep 2021 19.7 | Dec 2021 26.2 | Mar 2022 19.0 | Jun 2022 17.0 | Sep 2022 16.2 | Dec 2022 19.8 | Mar 2023 14.7 | Jun 2023 18.8 | Sep 2023 26.5 | Dec 2023 20.7 | Mar 2024 21.7 | Jun 2024 25.9 | Sep 2024 26.1 | Dec 2024 39.8 | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —
- KRSNAA: Sep 2021 -57.5 | Dec 2021 58.7 | Mar 2022 22.4 | Jun 2022 23.9 | Sep 2022 25.7 | Dec 2022 22.7 | Mar 2023 23.6 | Jun 2023 29.6 | Sep 2023 34.2 | Dec 2023 38.4 | Mar 2024 34.0 | Jun 2024 34.0 | Sep 2024 44.3 | Dec 2024 40.5 | Mar 2025 33.6 | Jun 2025 29.0 | Sep 2025 32.0 | Dec 2025 28.0 | Mar 2026 22.1 | Jun 2026 —
- SURAKSHA: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 2.2 | Mar 2025 2.4 | Jun 2025 48.5 | Sep 2025 43.8 | Dec 2025 44.2 | Mar 2026 36.9 | Jun 2026 —
- 3BBLACKBIO: Sep 2021 4.0 | Dec 2021 8.0 | Mar 2022 9.3 | Jun 2022 8.8 | Sep 2022 13.0 | Dec 2022 15.6 | Mar 2023 13.4 | Jun 2023 12.7 | Sep 2023 20.9 | Dec 2023 21.4 | Mar 2024 20.2 | Jun 2024 27.6 | Sep 2024 30.0 | Dec 2024 39.7 | Mar 2025 28.9 | Jun 2025 25.8 | Sep 2025 23.9 | Dec 2025 24.4 | Mar 2026 17.4 | Jun 2026 —


## What can make this comparison misleading?
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
- 3 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
- 1 company is missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.

## Every company
- Dr Lal Pathlabs Ltd (LALPATHLAB) — market value ₹31.9K Cr; latest fundamentals Jun 2026
- Vijaya Diagnostic Centre Ltd (VIJAYA) — market value ₹13.8K Cr; latest fundamentals Mar 2026
- Metropolis Healthcare Ltd (METROPOLIS) — market value ₹12.1K Cr; latest fundamentals Mar 2026
- Thyrocare Technologies Ltd (THYROCARE) — market value ₹9.2K Cr; latest fundamentals Jun 2026
- Vimta Labs Ltd (VIMTALABS) — market value ₹2.7K Cr; latest fundamentals Dec 2024; second-feed figures WITHHELD
- Krsnaa Diagnostics Ltd (KRSNAA) — market value ₹1.7K Cr; latest fundamentals Mar 2026; includes UNVERIFIED second-feed figures
- Suraksha Diagnostic Ltd (SURAKSHA) — market value ₹1.3K Cr; latest fundamentals Mar 2026; includes UNVERIFIED second-feed figures
- One Global Service Provider Ltd (514330) — market value ₹1.1K Cr; latest fundamentals Mar 2026
- 3B Blackbio DX Ltd (3BBLACKBIO) — market value ₹1.1K Cr; latest fundamentals Mar 2026; includes UNVERIFIED second-feed figures

## Source standing of each company

Cross-checked: 4. Unverified: 4. Withheld: 1. Graded companies: 9.

3 of 9 companies draw at least one figure from a second data feed that could not be cross-checked against the primary source, because the two do not share enough reported history to compare. Those figures are marked unverified wherever they appear.

1 of 9 companies has a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Vimta Labs Ltd (VIMTALABS) — its two data sources disagree by up to 64% on reported income across 13 comparable periods, so its derived ratios are withheld.

- WITHHELD | VIMTALABS | Vimta Labs Ltd | diff_gt_2pct | disagreement up to 63.77% over 13 comparable periods

- UNVERIFIED | KRSNAA | Krsnaa Diagnostics Ltd | too little overlapping reported history to cross-check the second feed
- UNVERIFIED | SURAKSHA | Suraksha Diagnostic Ltd | too little overlapping reported history to cross-check the second feed
- UNVERIFIED | 3BBLACKBIO | 3B Blackbio DX Ltd | too little overlapping reported history to cross-check the second feed

## Methodology and freshness

Fundamentals through Jun 2026; prices through 2026-07-31.
Up to 20 quarters per company. Reported history is normalized to Indian rupees crore. Missing values are not interpolated. Derived metrics are calculated only when their inputs are comparable.

## Frequently asked questions

### Is the Diagnostics sector outperforming NIFTY 500?

Diagnostics has outperformed NIFTY 500 by 10.9% over 52 weeks and 15.5% over 13 weeks. 6 of 9 covered companies beat NIFTY on Mansfield relative strength, while 5 of 9 beat the sector itself.

### Which Diagnostics company is largest by revenue?

Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 9 of 9 comparable companies through Jun 2026.

### Which Diagnostics company is growing fastest?

One Global Service Provider Ltd has the fastest current revenue growth at 100%, across 9 of 9 comparable companies.

### Which Diagnostics company has the strongest 4-Factor Sector Score?

Thyrocare Technologies Ltd ranks first at 77.4/100 with 100% evidence confidence. The score prioritizes research; it is not a buy recommendation.

### Which Diagnostics company has the lowest comparable PEG?

Thyrocare Technologies Ltd has the lowest comparable PEG at 1.1, among 4 of 9 companies whose earnings and growth are steady enough for the ratio to mean anything.

### How much history does this Diagnostics comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

### How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

### What is the Nifty Diagnostics index?

The Nifty Diagnostics index tracks India's listed Diagnostics companies as a single basket. This page follows the same 9 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Diagnostics sector rather than to its largest constituent. Figures are as of Jun 2026.

### Which are the best Diagnostics stocks in India?

Ranked by this page's four-factor score, Thyrocare Technologies Ltd places first among 9 listed Diagnostics companies, followed by Dr Lal Pathlabs Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

### How many Diagnostics stocks are listed in India?

This comparison covers 9 listed Diagnostics companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

### Which Diagnostics company is the biggest?

Dr Lal Pathlabs Ltd is the largest, with trailing-twelve-month revenue of ₹2,892 crore, ahead of Metropolis Healthcare Ltd at ₹1,646 crore. That covers 9 of 9 companies with comparable reporting through Jun 2026.

### Which Diagnostics company has the best profit margins?

Vijaya Diagnostic Centre Ltd has the highest operating margin at 44%, from 9 of 9 comparable companies. Metropolis Healthcare Ltd shows the biggest recent improvement, at +7 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

### Which Diagnostics company makes the most profit?

Dr Lal Pathlabs Ltd earns the most, at ₹545 crore of trailing-twelve-month net profit, from 9 of 9 comparable companies. One Global Service Provider Ltd has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.

### Which Diagnostics company earns the highest return on capital?

One Global Service Provider Ltd leads on return on capital employed at 87%, across 9 of 9 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

### Which Diagnostics stock is the cheapest?

On PEG — where a LOWER number is cheaper — Thyrocare Technologies Ltd screens cheapest at 1.1×. Only 4 of 9 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

### Is the Diagnostics sector beating the market?

Diagnostics has outperformed NIFTY 500 by 10.9% over the last 52 weeks and 15.5% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 6 of 9 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

### Which Diagnostics stock has the strongest price momentum?

Thyrocare Technologies Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

### Which Diagnostics company scores highest for research priority?

Thyrocare Technologies Ltd scores 77.4 out of 100 with 100% evidence confidence, from 27.9 points on growth and earnings, 18.1 on capital efficiency, 12 on valuation and 19.4 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

### How many Diagnostics companies does this comparison cover, and over what period?

It compares 9 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

### What is the total market cap of the Diagnostics sector?

The 9 Diagnostics companies on this page carry ₹74,996 crore of combined market value. Dr Lal Pathlabs Ltd is the largest at ₹31,938 crore, about 43% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-05.

### What is the Diagnostics sector's P/E ratio?

The median price-to-earnings ratio across the 9 Diagnostics companies on this page is 44.8×, measured on the 9 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-05.

### How is the Diagnostics sector performing?

6 of the 9 covered Diagnostics companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 10.9% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-05.

### Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

### Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.